Close Menu

siRNA

The technology is covered by 42 issued or allowed patents and 31 pending patent applications worldwide, according to Marina.

The partnership is expected to yield its first IND by 2012.

The combined grants are worth nearly $650,000 and are meant to support work on treatments for cancer and Huntington's disease.

The study is being conducted in Portugal, Sweden, and the UK and will enroll about 28 patients with the disease.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

The provisions for the EU orphan designation provide incentives to companies developing orphan drugs, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.

The deal marks the latest move by RXi to expand its access to new delivery approaches, and may offer some clues as to the therapeutic course RXi is setting for itself, which it will disclose at an investor conference this week.

Among the findings from the ongoing study was the suggestion of an anti-VEGF effect in the majority of treated patients.

The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.